Nanograb

About Nanograb

Nanograb utilizes AI-driven computational methods to design multivalent nanoparticles that enhance drug targeting to specific areas of the body. This approach aims to improve treatment efficacy for various diseases by optimizing the combination of binders used in drug formulations.

```xml <problem> Current drug delivery methods often lack precision, leading to systemic exposure and reduced efficacy. This non-specific targeting can result in off-target effects and limit the therapeutic potential of many drugs. </problem> <solution> Nanograb employs AI-driven computational methods to design multivalent nanoparticles that enhance drug targeting to specific areas of the body. By optimizing the combination of binders used in drug formulations, Nanograb's technology enables precise delivery of drugs to targeted tissues or cells. This approach aims to improve treatment efficacy for various diseases while minimizing off-target effects. The platform identifies optimal combinations of binders, facilitating the creation of nanoparticles with enhanced targeting capabilities. </solution> <features> - AI-driven computational platform for binder selection and optimization - Design of multivalent nanoparticles for targeted drug delivery - Enhanced drug targeting to specific areas of the body - Optimization of binder combinations for improved efficacy </features> <target_audience> The primary customers are pharmaceutical companies and research institutions seeking to improve drug delivery methods and enhance treatment efficacy. </target_audience> ```

What does Nanograb do?

Nanograb utilizes AI-driven computational methods to design multivalent nanoparticles that enhance drug targeting to specific areas of the body. This approach aims to improve treatment efficacy for various diseases by optimizing the combination of binders used in drug formulations.

Where is Nanograb located?

Nanograb is based in San Francisco, United States.

When was Nanograb founded?

Nanograb was founded in 2023.

How much funding has Nanograb raised?

Nanograb has raised 500000.

Who founded Nanograb?

Nanograb was founded by Debesh Mandal.

  • Debesh Mandal - Co-founder/CEO
Location
San Francisco, United States
Founded
2023
Funding
500000
Employees
6 employees
Major Investors
Y Combinator
Looking for specific startups?
Try our free semantic startup search

Nanograb

Score: 100/100
AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

Nanograb utilizes AI-driven computational methods to design multivalent nanoparticles that enhance drug targeting to specific areas of the body. This approach aims to improve treatment efficacy for various diseases by optimizing the combination of binders used in drug formulations.

nanograb.com500+
cb
Crunchbase
Founded 2023 – San Francisco, United States

Funding

$

Estimated Funding

$500K+

Major Investors

Y Combinator

Team (5+)

Debesh Mandal

Co-founder/CEO

Company Description

Problem

Current drug delivery methods often lack precision, leading to systemic exposure and reduced efficacy. This non-specific targeting can result in off-target effects and limit the therapeutic potential of many drugs.

Solution

Nanograb employs AI-driven computational methods to design multivalent nanoparticles that enhance drug targeting to specific areas of the body. By optimizing the combination of binders used in drug formulations, Nanograb's technology enables precise delivery of drugs to targeted tissues or cells. This approach aims to improve treatment efficacy for various diseases while minimizing off-target effects. The platform identifies optimal combinations of binders, facilitating the creation of nanoparticles with enhanced targeting capabilities.

Features

AI-driven computational platform for binder selection and optimization

Design of multivalent nanoparticles for targeted drug delivery

Enhanced drug targeting to specific areas of the body

Optimization of binder combinations for improved efficacy

Target Audience

The primary customers are pharmaceutical companies and research institutions seeking to improve drug delivery methods and enhance treatment efficacy.